<DOC>
	<DOCNO>NCT03054519</DOCNO>
	<brief_summary>The PERMET trial determine whether metformin daily six month improve walk performance individual peripheral artery disease compare placebo .</brief_summary>
	<brief_title>Improve PAD PERformance With METformin</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>All participant PAD . PAD define follow . First , ankle brachial index ( ABI ) &lt; 0.90 baseline study visit inclusion criterion PAD . Second , potential participant ABI &gt; 0.90 â‰¤ 1.00 experience 20 % high drop ABI heelrise exercise eligible . Third , potential participant ABI &gt; 0.90 vascular lab evidence PAD angiographic evidence PAD ischemic symptom sixminute walk and/or treadmill exercise stress test eligible . Fourth , potential participant history low extremity revascularization meet criterion ABI &gt; 0.90 20 % high drop ABI heelrise exercise eligible . 1 . Above belowknee amputation . 2 . Critical limb ischemia . 3 . Wheelchairbound require walker ambulate . 4 . Walking limited symptom PAD . 5 . Current foot ulcer bottom foot . 6 . Diabetes mellitus define one ) patient report physician diagnose diabetes mellitus , b ) use one diabetes medication , c ) baseline hemoglobinA1C value &gt; 6.5 , ) two fast glucose value &gt; 126 mg/dl . [ NOTE : second fast glucose value discretion principal investigator . For example , first value &gt; 300 , investigator may decide repeat value . ] 7 . Chronic kidney disease define GFR &lt; 45 . [ NOTE : GFR 4044 , investigator discretion use determine repeat test may perform . If second GFR value &gt; 45 , participant may include . ] 8 . Chronic liver disease define two hepatic function test &gt; 2.0 time upper limit normal . [ NOTE : participant meet criterion may undergo retest hepatic function test determine whether initially elevate hepatic enzyme represent transient spurious phenomenon . ] 9 . Failure successfully complete 2week study runin , define unable tolerate metformin and/or fail take medication daily 10 day twoweek period . 10 . Planned low extremity revascularization , orthopedic surgery , major surgery next six month . 11 . Lower extremity revascularization , orthopedic surgery , cardiovascular event , coronary revascularization , major surgery previous three month . 12 . Major medical illness include renal disease require dialysis , lung disease require oxygen , Parkinson 's disease , lifethreatening illness life expectancy less six month , cancer require treatment previous two year . [ NOTE : potential participant may still qualify treatment early stage cancer past two year prognosis excellent . Participants use oxygen night may still qualify . ] 13 . MiniMental Status Examination ( MMSE ) score &lt; 23 dementia . 14 . Participation completion clinical trial previous three month . [ NOTE : completing stem cell gene therapy intervention , participant become eligible final study followup visit stem cell gene therapy study long least six month pass since final intervention administration . After complete supplement drug therapy ( stem cell gene therapy ) , participant eligible final study followup visit long least three month pass since final intervention trial . ] 15 . Currently take metformin take metformin past six month . 16 . Increase angina angina rest 17 . NonEnglish speaking . 18 . Visual impairment limit walk ability . 19 . In addition criterion , investigator discretion use determine trial unsafe good fit potential participant . Vulnerable population ( fetus , pregnant woman , child , prisoner , institutionalized person ) adult unable consent include study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>